Seattle biotech firm Umoja Biopharma raises $53M as it tackles unique approach to immunotherapy

Umoja Biopharma CEO Andy Scharenberg. (Umoja Photo)

Umoja Biopharma raised $53 million to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients.

Founded last year, the pre-clinical Seattle-based company says it is taking a new three-step approach to

This post was originally published on this site


Check out